slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 73,381-73,410
Pages 3,679
Rows per page 30
Component
73,381-73,410 of 110,355
107
The slide uses a combination of a horizontal bar chart and a data table to quantify the addressable market.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
05
The chart plots UC maintenance remission rates against maintenance dosing frequency, showing current standard-of-care drugs clustered at lower efficacy and higher frequency, while the 'Spyre Target' is positioned at higher efficacy and lower frequency.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a three-column layout to present distinct technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
The slide uses a structural biology visualization and two dose-response curves to establish bio-equivalence and differentiation.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
11
The slide uses two semi-logarithmic line charts to compare drug concentration decay over time.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
14
The slide uses a comparative bar chart approach to justify the human half-life prediction based on NHP data.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
16
The slide uses a combination of a pharmacokinetic simulation line chart and a bar chart showing clinical remission rates by exposure quartile.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a comparative table for safety metrics and a bar chart for ADA rates to establish clinical equivalence/safety.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Competition1 hit
29
The slide uses a stacked bar chart to visualize the additive clinical remission rates, noting a 22% delta between the individual components and the combination.Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
30
Aeglea BioTherapeutics | Investor Presentation Deck | 37 slidesAeglea BioTherapeutics | Investor Presentation Deck | 37 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
05
The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
06
The slide uses a three-column layout to present the company's core technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
10
Includes structural biology visualization, dose-response curves, and a binding affinity table.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
11
Pharmacokinetic study results showing extended half-life for the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
14
Includes PK modeling data comparing human and NHP half-lives and steady-state concentration simulations.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
16
The slide uses a bar chart to show dose-response correlation and a line chart to show pharmacokinetic modeling.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
18
The slide uses two distinct data visualizations: a table for clinical safety metrics and a bar chart for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses two distinct chart types: a scatter plot for binding affinity and a dose-response curve for functional inhibition.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a timeline to frame recent industry activity as validation for the company's asset.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
30
The chart uses a stacked bar to visualize the additive nature of the combination therapy compared to the individual components.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
31
The table highlights that Spyre's products possess specific safety and efficacy features (no black box warning, dual mechanism, extended half-life) that the competitor lacks.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
35
The slide combines financial runway with a clinical development timeline.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
05
The slide uses a split-image layout to define the film's visual world-building.AKT Pictures | Other Presentation Deck | 17 slides · akt-pictures
Deck Investor relations Beat · Ordinary WorldLoop · Golden Circle1 hit
05
The slide uses a numbered list format to present five key highlights about the company's spin-off status, cytokine portfolio, and specific drug program progress.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
06
The slide uses a Gantt-style chart to map drug development stages across different indications.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations 1 hit
08
The diagram illustrates the interaction between T cells, tumor cells, and cytokines (IL-2, IL-12, IL-18) and the mechanism of checkpoint inhibitors.Alkermes | Investor Presentation Deck | 37 slides · Mural Oncology
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit